{"id":"NCT04882241","sponsor":"Merck Sharp & Dohme LLC","briefTitle":"Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585)-China Extension","officialTitle":"A Phase III, Randomized, Double-Blind, Clinical Trial of Pembrolizumab (MK-3475) Plus Chemotherapy (XP or FP) Versus Placebo Plus Chemotherapy (XP or FP) as Neoadjuvant/Adjuvant Treatment for Subjects With Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma (KEYNOTE-585)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2020-07-29","primaryCompletion":"2024-02-16","completion":"2025-04-23","firstPosted":"2021-05-11","resultsPosted":"2025-02-20","lastUpdate":"2025-06-12"},"enrollment":120,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Gastric Cancer","Gastroesophageal Junction Cancer"],"interventions":[{"type":"BIOLOGICAL","name":"Pembrolizumab","otherNames":["MK-3475","KEYTRUDA®"]},{"type":"DRUG","name":"Placebo","otherNames":["Normal saline solution"]},{"type":"DRUG","name":"Cisplatin","otherNames":["PLATINOL®"]},{"type":"DRUG","name":"Capecitabine","otherNames":["XELODA®"]},{"type":"DRUG","name":"5-fluorouracil","otherNames":["ADRUCIL®","5FU"]},{"type":"DRUG","name":"Docetaxel","otherNames":["TAXOTERE®"]},{"type":"DRUG","name":"Oxaliplatin","otherNames":["ELOXATIN®"]},{"type":"DRUG","name":"Leucovorin","otherNames":["WELLCOVORIN®"]}],"arms":[{"label":"Pembrolizumab+XP/FP","type":"EXPERIMENTAL"},{"label":"Placebo+XP/FP","type":"PLACEBO_COMPARATOR"},{"label":"Pembrolizumab+FLOT Cohort","type":"EXPERIMENTAL"},{"label":"Placebo+FLOT Cohort","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this study is to evaluate the efficacy of pembrolizumab (MK-3745) in the neoadjuvant (prior to surgery) or adjuvant (after surgery) treatment of previously untreated Chinese adults with gastric and gastroesophageal junction (GEJ) adenocarcinoma. No formal hypothesis testing will be done.","primaryOutcome":{"measure":"Event-free Survival (EFS) Per Response Criteria in Solid Tumors Version 1.1 (RECIST 1.1) - Pembrolizumab+XP/FP and Placebo+XP/FP Treatment Arms","timeFrame":"Up to approximately 42 months","effectByArm":[{"arm":"Pembrolizumab + XP/FP","deltaMin":null,"sd":null},{"arm":"Placebo + XP/FP","deltaMin":36.5,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.39528"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":8,"exclusionCount":16},"locations":{"siteCount":20,"countries":["China"]},"refs":{"pmids":[],"seeAlso":["https://merckclinicaltrials.com/"]},"adverseEventsSummary":{"seriousAny":{"events":32,"n":59},"commonTop":["Neutrophil count decreased","Nausea","Anaemia","White blood cell count decreased","Vomiting"]}}